Summary
Five patients with a creatinine clearance of 14 to 37 ml/min/1.73 m2 were each given an oral dose of 10 mg of the beta-blocker mepindolol sulphate (Corindolan). In addition, two dialysis patients received the same dose either during hemodialysis or on a dialysis-free day. Plasma levels of mepindolol were measured by a sensitive, specific HPLC method. Mepindolol was rapidly absorbed in all the patients. The maximum plasma level of 35±8 ng/ml was reached after 1.4±0.5 h. The half-life of disposition was 4.0±1.5 h. The area under the plasma concentration-time curve was 237±84 ng × h/ml. The data obtained were no different from those found in normal healthy volunteers.
Similar content being viewed by others
References
Bolte H-D (1982) Betarezeptorenblocker, Pharmakokinetik und therapeutische Wirksamkeit. Internist 23: 616–623
Simon P, Meyrier A, Brissot P (1981) Uremia and the liver II. Drugs and the liver in the uremic patient. Nephron 29: 7–13
Aellig WH (1973) Isoprenaline antagonism and duration of action in exercise induced tachycardia of three β-adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol. Br J Pharmacol 47: 621 P
Carrageta M (1982) Nicht-invasive Blutdrucküberwachung unter der Therapie mit Beta-Blockern. In: Hitzenberger G, Berzewski B (eds) Beta-Rezeptoren-Antagonisten in der Therapie der koronaren Herzkrankheit und der Hypertonie. Dustri-Verlag Karl Feistle, München-Deisenhofen, p 137–143
Raftery EB (1983) Klassifizierung der Beta-Blocker nach ihrer Wirkung auf Blutdruckschwankungen im tagesperiodischen Verlauf. In: Magometschnigg D, Hitzenberger G (eds) Blutdruckvariabilität. Uhlen Wien, p 109–117
Krause W, Kühne G, Täuber U (1980) Pharmacokinetics of mepindolol sulphate in animals. Eur J Drug Metab Pharmacokinet 5: 241–247
Hellenbrecht D, Lemmer B, Wiethold G, Grobecker H (1973) Measurement of hydrophobicity, surface activity, local anaesthesia and myocardial conduction velocity as quantitative parameters of the non-specific membrane activity of nine β-adrenergic blocking agents. Naunyn-Schmiedebergs Arch Pharmacol 277: 211–226
Bonelli J, Hitzenberger G, Krause W, Wendt H, Speck U (1980) Pharmacokinetics and pharmacodynamics of mepindolol sulphate. Int J Clin Pharmacol Ther Toxicol 18 [4]: 169–176
Krause W (1980) Determination of plasma mepindolol levels by high-performance liquid chromatography and electrochemical detection. J Chromatogr 181: 67–75
Krause W, Schwartzkopff W (1983) Plasma levels of mepindolol in healthy volunteers after oral doses of mepindolol sulphate. Arzneimittelforsch 33: 1306–1307
Ohnhaus EE, Nuesch E, Meier J, Kalberer F (1974) Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia. Eur J Clin Pharmacol 7: 25–29
Ohnhaus EE (1973) The pharmacokinetics of unchanged pindolol in patients with impaired renal function. Br J Pharmacol 47: 620–621
Oie S, Levy G (1975) Relationship between renal function and elemination kinetics of pindolol in man. Eur J Clin Pharmacol 9: 115–116
Ohnhaus EE, Heidemann H, Meier J, Maurer G (1982) Metabolism of pindolol in patients with renal failure. Eur J Clin Pharmacol 22 [5]: 423–428
Lavene D, Weiss YA, Safar ME, Loria Y, Agorus N, Georges D, Milliez PC (1977) Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol 17: [8]: 501–508
Wood AJJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG (1980) Propranolol, disposition in renal failure. Br J Clin Pharmacol 10: 561–566
Blair AD, Burgess ED, Maxwell BM, Cutler RE (1981) Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 29 [4]: 457–463
Berglund G, Descamps R, Thomis JA (1980) Pharmarcokinetics of sotalol after chronic administration to patients with renal insufficiency. Eur J Clin Pharmacol 18: 321–326
Kirch W, Köhler H, Mutschler E, Schäfer M (1981) Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19: 65
McAinsh J, Holmes BF, Smith S, Hood D, Warren D (1980) Atenol kinetics in renal failure. Clin Pharmacol Ther 28 [3]: 302–309
Bianchetti G (1982) Betaxolol disposition in chronic renal insufficiency, hemodialysis and ambulatory peritoneal dialysis. Eur J Clin Invest 12 [2]: 2–5
Munn S, Bailey RR, Begg E, Ebert R (1980) Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment. NZ Med J 91: 289–291
Fabre J, Balant L, Rudhardt M, Blanchard P (1979) Particulations de la pharmacocinetique dans l'insuffisance renale: anomalie des metabolites et de la diffusion dans les tissus. Nouv Presse Méd 8: 2677–2682
Seiler KU, Schuster KJ, Meyer G-J, Niedermayer W, Wassermann O (1980) The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet 5: 192–198
Krause W (1982) The role of HPLC in pharmacokinetics. In: Molnar I (ed) Practical aspects of modern HPLC. de Gruyter, Berlin New York, p 197
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krause, W., Kampf, D. & Fischer, H.C. Pharmacokinetics of mepindolol in patients with chronic renal failure. Eur J Clin Pharmacol 27, 429–433 (1984). https://doi.org/10.1007/BF00549590
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00549590